Tetanus Toxoid
Relapsing-Remitting Multiple Sclerosis
Explore 71 assets in Relapsing-Remitting Multiple Sclerosis →Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Celgene
Modality
vaccine
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
50High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05028634CT.gov Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy | — | Completed | — | — | — |
NCT01199861CT.gov Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Relapsing-Remitting Multiple Sclerosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tetanus Toxoid (this asset) | Celgene | P3 | B · 60 |
| Natalizumab | Biogen | P4 | BBB |
| Glatiramer | University Hospital, Montpellier | P4 | BBB |
| Fingolimod | TG Therapeutics, Inc. | P4 | BBB |
| Interferon ?1 (Human Fibroblast Protein Moiety) | Biogen | P4 | BBB |
| 2-BUTENEDIOIC ACID, (2E)-, DIMETHYL ESTER | University Hospital, Montpellier | P4 | BBB |
| Cladribine | Uppsala University | P4 | BBB |
| Ocrelizumab | Biocad | P4 | BBB |
| Phytonadione, (E)-(±)- | Biogen | P4 | BBB |
+42 more in the Relapsing-Remitting Multiple Sclerosis cohort
Other indications for Tetanus Toxoid
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Multiple Sclerosis | — | P4 | B · 63 |
| Plasma Cell Myeloma | — | P2 | B · 59 |
| Ovarian Serous Adenocarcinoma | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tetanus Toxoid in Relapsing-Remitting Multiple Sclerosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tetanus-toxoid-relapsing-remitting-multiple-sclerosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →